Sanofi to curtail R&D activity at Hungarian subsidiary

Paris-based pharmaceutical company Sanofi will eliminate first-phase R&D activity at its Hungarian subsidiary Chinoin, the latter company’s Communications Director Iván Rózsa told MTI on Tuesday evening.

The move is part of global restructuring of R&D activities within the Sanofi group, he said.

Rózsa emphasized that Chinoin would continue to conduct later-phase R&D activity in the country. These could bear results more rapidly and are export-oriented, he said.

The elimination of initial-phase R&D activity will affect 160 employees at Chinoin, Rózsa said.

Figures

VC Investments in CEE at EUR 940 mln in Q2 2024 – Vestbee

World

American Hungarian Diaspora Org Sets Sights on Young People

Energy Trade

Ganz’s Giant Transformer to Connect Hungarian and Eastern European Power Grids

Budapest

Karácsony: Budapest Ready for Flood Wave

SUPPORT THE BUDAPEST BUSINESS JOURNAL

Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.